AngioDynamics, Inc. reported a revenue increase of 9.5% for the fiscal year ending May 31, 2026, reaching $320.2 million compared to $292.5 million in the previous year. The growth was primarily driven by a significant 18.4% increase in the Med Tech segment, which includes products like the Auryon and NanoKnife systems, while the Med Device segment saw a more modest growth of 2.6%. Despite the revenue growth, the company experienced a net loss of $36.7 million, an increase of $2.7 million from the prior year, resulting in a loss per share of $0.88.

The company’s operational performance was influenced by various strategic initiatives, including a restructuring plan aimed at optimizing manufacturing efficiency. This plan is expected to generate annual cost savings of approximately $15 million starting in fiscal year 2027. Additionally, AngioDynamics has focused on expanding its product offerings and enhancing its research and development capabilities, which included the enrollment of patients in multiple clinical trials and the receipt of FDA approvals for several products. The company also divested certain product lines, including the BioSentry and dialysis businesses, to streamline operations and focus on higher-margin products.

In terms of geographic performance, AngioDynamics reported that U.S. sales accounted for the majority of its revenue, totaling $274.9 million, while international sales increased to $45.3 million. The company’s gross margin improved to 54.6%, up from 53.9% in the previous year, attributed to increased sales volume and favorable product mix, although it faced challenges from tariffs and inflationary pressures.

As of May 31, 2026, AngioDynamics had approximately 632 full-time employees and maintained a cash balance of $53.9 million, with no outstanding debt. The company’s liquidity position is deemed sufficient to meet its anticipated capital needs for at least the next 12 months. Looking ahead, AngioDynamics aims to continue its focus on innovative product development and market expansion, while navigating the challenges posed by the current macroeconomic environment, including inflation and supply chain disruptions.

About ANGIODYNAMICS INC

AngioDynamics, Inc. is a diversified medical technology company focused on enhancing treatment options for cardiovascular diseases and cancer. Its key products include the Auryon Atherectomy System and various thrombus management devices. With a growing market opportunity, AngioDynamics targets interventional radiologists and oncologists. The company emphasizes innovation through R&D and strategic acquisitions, aiming to improve patient outcomes and expand its product offerings in the competitive medical device landscape.

This description was generated via AI from an annual report. Updated 10 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.